title: Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?
authors.forename: Amedeo Ferdinando
authors.initials: AF
authors.lastname: Capetti
authors.forename: Stefania
authors.initials: S
authors.lastname: Piconi
authors.forename: Simona
authors.initials: S
authors.lastname: Landonio
authors.forename: Giuliano
authors.initials: G
authors.lastname: Rizzardini
authors.forename: Carlo Federico
authors.initials: CF
authors.lastname: Perno
mesh_terms: D000328:Adult; D000368:Aged; D000069454:Darunavir; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000627:therapeutic use; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011760:Pyrrolidinones / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D016879:Salvage Therapy; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D019428:HIV Integrase Inhibitors; D017320:HIV Protease Inhibitors; D011760:Pyrrolidinones; D013449:Sulfonamides; D000068898:Raltegravir Potassium; D000069454:Darunavir